St. Jude Medical Inc. ( STJ ) revealed that it has received CE Mark approval for its Prodigy implantable neuromodulation device that is capable of helping patients suffering from chronic pain with reduced paresthesia using Burst Technology. The company has launched the device in Europe. However, the news failed to entice investors as stock price fell 1.6% to $65.34.
Help employers find you! Check out all the jobs and post your resume.
